The global osteoporosis drugs market is projected to exhibit sluggish growth by the end of 2025 with escalating demand for these drugs across the globe for the treatment of ailments such as prophylaxis. The wide range of pipeline drugs are expected to create new revenue prospects in the market. Growing osteoporosis conditions bred by the sedentary lifestyle is expected to drive the adoption rate of these drugs in the coming years.
Find Out More about the Report Coverage
Top companies profiled in this report are:
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Merck & Co, Inc.
- Novartis AG
- Amgen, Inc.
- Novo Nordisk A/S
- Actavis plc
- Pfizer, Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd
Effect of Covid-19
COVID-19 pandemic is expected to reduce the demand for a brief time period owing to a reduction in reported cases of ailments. The market is expected to witness a surge in demand with growing relaxations in people's movements. North America is projected to hold major market share by the end of the forecast period owing to enhanced research & development activities and high medical standards. Burgeoning investments are expected to impart a high growth rate to the osteoporosis market in the Asia Pacific, creating new revenue pockets to the manufacturers.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
The market players are adopting collaborative strategies to sustain market competition. The manufactures are investing in research and development to introduce innovative products in the market. Established players in the market include Novo Nordisk A/S, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., and Novartis AG.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market. However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits growth of the market.
The osteoporosis drugs market is anticipated to grow from an estimated US$11,226.1 Mn in 2015 to account for US$14,786.7 Mn by 2022 at a CAGR of 4.0% during the forecast period. North America is the largest market for osteoporosis drugs, with bisphosphonates being the most popular type of osteoporosis drugs. Asia-Pacific is the fastest growing region in terms of revenue while RANK ligand inhibitors are the fastest growing type of osteoporosis drugs.
Explore Persistence Market Research’s expertise in promulgation of the business !
Bisphosphonates are the most commonly prescribed medication for treatment and prevention of osteoporosis. The global bisphosphonates drugs market is expected to grow from an estimated US$5,482.6 Mn in 2015 to US$7,342.2 Mn by 2022 at a CAGR of 4.3% during the forecast period.
This report provides in-depth analysis and estimation of the osteoporosis drugs market for 2015– 2022, considering 2014 as the base year for calculation. Moreover, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report.
Parathyroid Hormone Therapy Drugs
Selective Estrogen Receptors Modulators (SERMs)
RANK Ligand Inhibitors
France, Germany, and the UK
Rest of Europe
Rest of Asia Pacific